Xeris Biopharma (NASDAQ:XERS) Announces Quarterly Earnings Results

Xeris Biopharma (NASDAQ:XERS) announced its quarterly earnings results on Thursday. The company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.05, Zacks reports. Xeris Biopharma updated its FY 2025 guidance to EPS.

Xeris Biopharma Stock Up 15.5 %

XERS stock traded up $0.58 during trading on Thursday, reaching $4.35. The company’s stock had a trading volume of 3,722,688 shares, compared to its average volume of 1,686,455. The company’s fifty day moving average is $3.54 and its 200-day moving average is $3.24. Xeris Biopharma has a 1 year low of $1.69 and a 1 year high of $4.50. The company has a market capitalization of $648.95 million, a P/E ratio of -9.67 and a beta of 2.32.

Wall Street Analyst Weigh In

Several research analysts have issued reports on XERS shares. Piper Sandler cut Xeris Biopharma from an “overweight” rating to a “neutral” rating and set a $3.00 target price on the stock. in a research report on Monday, November 11th. HC Wainwright upped their target price on shares of Xeris Biopharma from $6.00 to $6.60 and gave the company a “buy” rating in a report on Monday, November 11th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $6.00 price target (up from $4.00) on shares of Xeris Biopharma in a research report on Wednesday, January 29th.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.